Skip to main content
Midas Edge

Enliven Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 14, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 14, 2024

ELVN$51.55+4.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 16. Form 10-K Summary

None.

Exhibit Index

Incorporated by Reference
ExhibitNumberDescriptionFormFile No.ExhibitFiling Date
1.1Open Market Sale AgreementSM, dated June 23, 2023, by and between Enliven Therapeutics, Inc. and Jefferies LLC8-K001-392471.1June 26, 2023
2.1Agreement and Plan of Merger, dated as of October 13, 2022, by and among Imara Inc., Iguana Merger Sub, Inc. and Enliven Therapeutics, Inc.8-K001-392472.1October 13, 2022
3.1The Company's Restated Certificate of Incorporation, as amended February 23, 202310-Q001-392473.1May 11, 2023
3.2Amended and Restated Bylaws of the Registrant8-K001-392473.2March 16, 2020
4.1Specimen Common Stock Certificate of the RegistrantS-3333-2729094.1June 23, 2023
4.2Description of the Registrant’s SecuritiesFiled herewith
10.1*Contingent Value Rights Agreement between the Company and Rights Agent8-K001-3924710.1March 1, 2023
10.2+Amended and Restated 2020 Equity Incentive Plan8-K001-3924710.2March 1, 2023
10.3+2020 Employee Stock Purchase PlanFiled herewith
10.4+Rahul Ballal Separation Agreement, dated February 23, 20238-K001-3924710.6March 1, 2023
10.5+Michael Gray Separation Agreement, dated February 23, 20238-K001-3924710.7March 1, 2023
10.6+*Sam Kintz Confirmatory Employment Letter, as amended and restated February 29, 2024Filed herewith
10.7+*Helen Collins Confirmatory Employment Letter, as amended and restated February 29, 2024Filed herewith
10.8+*Benjamin Hohl Confirmatory Employment Letter, as amended and restated February 29, 2024Filed herewith
10.9+*Joseph Lyssikatos Confirmatory Employment Letter, as amended and restated February 29, 2024Filed herewith
10.10+*Anish Patel Confirmatory Employment Letter, as amended and restated February 29, 2024Filed herewith
10.11+Sam Kintz Change in Control and Severance Agreement, as amended and restated February 29, 2024Filed herewith
10.12+Helen Collins Change in Control and Severance Agreement, as amended and restated February 29, 2024Filed herewith
10.13+Benjamin Hohl Change in Control and Severance Agreement, as amended and restated February 29, 2024Filed herewith
10.14+Joseph Lyssikatos Change in Control and Severance Agreement, as amended and restated February 29, 2024Filed herewith
10.15+Anish Patel Change in Control and Severance Agreement, as amended and restated February 29, 2024Filed herewith
10.16+Outside Director Compensation Policy, as amended February 13, 2024Filed herewith
10.17+#*Consulting Agreement between Richard Heyman and Former EnlivenS-4/A333-26830010.5January 9, 2023
10.18+Form of Indemnification Agreement of the Company8-K001-3924710.16March 1, 2023
10.19+Enliven 2019 Equity Incentive Plan, as amended, including forms of agreements thereunderS-4333-26830010.2November 10, 2022
10.20+Employee Incentive Compensation Plan8-K001-3924710.18March 1, 2023
21.1List of Subsidiaries of Enliven Therapeutics, Inc.Filed herewith
23.1Consent of Independent Registered Public Accounting FirmFiled herewith
24.1Power of Attorney (included on the signature page to this Annual Report on Form 10-K)Filed herewith
31.1Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Filed herewith
31.2Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Filed herewith
32.1**Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Furnished herewith
32.2**Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Furnished herewith
97.1Compensation Recovery PolicyFiled herewith
101.INSINLINE XBRL Instance DocumentFurnished herewith
101.SCHINLINE XBRL Taxonomy Extension Schema with Embedded Linkbase DocumentsFurnished herewith
104Cover Page Interactive Data File (embedded within the Inline XBRL document)Furnished herewith
+Management contract or compensatory plan.
#Certain exhibits or schedules to this exhibit have been omitted in compliance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.
*Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6).
**The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Enliven Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.